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Abstract 
Malaria is a human infectious disease that affects around 250 million people 
each year. Primarily found in regions of Africa, Asia, and South America, malaria is 
typically caused by the protozoa Plasmodium falciparum, and results in symptoms 
ranging from high fever to death. The most common detection methods currently 
consist of ELISA, PCR, and blood film smears; however, each of these methods requires a 
full laboratory environment for proper utilization, with assay times ranging from 2-8 
hours. In this study, a novel handheld detection device based on the properties of 
immunoagglutination will be modified to detect malaria in human whole blood through 
histidine-rich protein 2 (HRP-2), an antigen expressed only by P. falciparum. HRP-2 
antibodies are covalently attached to 920 µm carboxylated polystyrene nanoparticles, 
which are mixed with the target human whole blood in a lab-on-chip testing 
environment. Using a 640 nm LED and avalanche photodiode pair, the sample is 
illuminated and forward light scatter caused by immunoagglutination of the HRP-2 
antigen to the antibodies present on the nanoparticles is measured. The final device is 
compact, battery powered, low-cost, and capable of detecting HRP-2 antigens in human 
whole blood with a detection limit of 1 pg/ml and an assay time of approximately 8 
minutes. The device represents a significant improvement in assay time over current 
malaria detection methods at a relatively low cost. 
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1.1- Malaria Background 
Section 1 
Introduction 
1.1.1- Introduction and History 
Malaria is a human parasitic disease that results in a variety of symptoms 
depending on its severity, ranging from chills and headaches to anemia, acute kidney 
failure, and death. Although not a common condition in developed nations, malaria 
remains a common and serious condition throughout parts of Africa, Asia, and South 
America. Malaria may very well be a condition that is as old as humanity itself, with 
written accounts matching its common characteristics dating as far back as Chinese 
medical writings in 2700 BC. Additional references to the then-unnamed "sickness" that 
resulted in fever and death were recorded in various parts of the world up until 1740, 
when it was given the formal name of malaria. Its name was given by H. Walpole, 
derived from the Italian expression "mal'aria" for "bad air", due to the observation that 
the disease was transferred through airborne means (Desowitz, 1991}. 
The parasitic nature of malaria was first ,discovered by Charles Louis Alphone 
Laveran in 1880. A French army surgeon, Laveran was treating a malaria-stricken soldier 
when he observed parasites in his blood, a fact later confirmed by French immunologist 
Pierre Paul Emile Roux. In 1886, Italian neurophysiologist Camillo Golgi reported that 
there were at least two different forms of the disease, with symptoms differing 
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depending on the type. Lastly, around 1897, British officer Ronald Ross was the first to 
observe that malaria could be transmitted through mosquito bites (Cox, 2010). 
1.2.1-Causes and Symptoms 
Malaria results from infection by eukaryotic protozoa of the genus Plasmodium, 
which invade the bloodstream and infect red blood cells. The disease originates in 
Anopheles mosquitoes, where certain species of Plasmodium reside within the salivary 
glands of carrier mosquitoes. When a carrier mosquito withdraws a blood meal from a 
human, the parasites are passed into the bloodstream and infect an initial batch of red 
blood cells. The parasites will then differentiate over the course of 48-72 hours and 
begin infection of new red blood cells. Incubation times vary depending on Plasmodium 
species, with symptoms showing as quickly seven days after initial infection but 
potentially taking up to thirty days or more (Heussler, 2006). 
Malaria can be grossly classified by severity into two categories - uncomplicated 
and severe. Uncomplicated malaria is rarely fatal, and is typically characterized by 
headaches, chills, increased sweating, nausea, vomiting, and achiness. Physical effects 
may include mild jaundice, an enlarged spleen and/or liver, and increased respiratory 
rate. In some cases, these symptoms occur in waves, with each series of symptoms 
lasting six to ten hours before receding for up to several days; these kinds of attacks are 
infrequently observed, however. The symptoms of a severe infection are far less 
general, and include high fever, anemia due to hemolysis, low blood pressure (often the 
result of cardiovascular collapse), metabolic acidosis, acute respiratory distress 
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syndrome (ARDS), and in some cases, a range of neurological conditions including 
unconsciousness, seizures, or coma. Severe malaria infections can often lead to organ 
failure and death if not treated quickly and properly (Miller, 2002). 
1.3.1- Biology and Species 
P/asmodium is part of the protest group Apicomplexa, which are spore-forming, 
unicellular, and exist exclusively as parasites. They possess a unique cone-shaped 
projection of their cell membrane, known as the apical complex, which is instrumental 
in penetrating and infecting the host cell. 
The lifecycle of a malarial infection occurs in three stages - the mosquito stage, 
the hepatic stage, and the blood stage. As previously mentioned, malaria originates in 
Anopheles mosquitoes and are prepped for human infection in the mosquito stage. 
Initially, male and female gametocytes, or parasite gametes formed by meiosis, combine 
to form zygotes within the mosquito. These zygotes mature into ookinetes, which then 
penetrate the mosquito's midgut in order to take up residence under the outer gut 
lining. Here, the ookinetes mature further into oocysts, which develop and eventually 
rupture, releasing infectious sporozites that move into the mosquto's salivary glands 
(Tripet, 2008). 
Upon blood contact with a human host, anywhere from 5-200 sporozites will be 
transferred by the mosquito. These sporozites will travel to the liver and infect hepatic 
cells, where they will develop and eventually rupture, releasing merozites while 
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destroying the red blood cell host. These merozites will continue to multiply in the liver, 
eventually re-infecting new red blood cells using their apical complexes; the parasite will 
then shed its apical complex and become a trophozite, which is the activated form of 
malaria found in the red blood cell cytoplasm. The trophozite stage is also referred to as 
the " ring" stage, due to their physical appearance in a blood smear detection test 
(Pouvelle, 2000). As the trophozites feed on the hemoglobin of host cells, they will 
increase in size considerately to around lSµm in diamter, developing into schizonts 
which will replicate their DNA multiple times before segmenting into anywhere from 15-
20 new merozitic cells. Thus, the infection will spread, and some merozites will 
eventually mature into gametocytes that can be extracted by feeding mosquitoes, 
bringing the malarial lifecycle full-circle (Pouniotis, 2004). Figure 1 summarizes the 
infectious lifecycle of Plasmodium parasites. 
Malaria Human Liver Stages 
rPlmmo,lmm .,pp.) 
A = lnfectf\le SlagfJ: 
A; Oiagnos lic Stage cf 
Figure 1 - Plasmodium lifecycle. (CDC, 2010) 
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Although there are approximately 200 known species of Plasmodium, only 
eleven are known to be infectious to humans, and four are known to cause malaria. The 
four species that cause malaria are Plasmodium falciparum, Plasmodium malariae, 
Plasmodium ovate, and P/asmodium vivax. P. malaria, P. ovate, and P. vivax are 
responsible for cases of uncomplicated malaria, and thus, represent mild forms of the 
disease which are typically non-deadly and easily curable, whereas P. fa/ciparum causes 
severe malaria and is responsible for 90% of all malaria-related deaths (Bain, 2009) 
Whereas P. falciparum and P. malariae have incubation times of less than 30 days, P. 
ovate can remain dormant in the liver for up to two years before causing symptoms, and 
P. vivax can take up to four years. Each of the malaria-causing species follows similar 
infection patterns and lifecycles, but are distinguishable under a microscope due to 
subtle physical characteristics. These differences will be further discussed in Section 
1.2.3 - Peripheral Blood Smears. 
1.4.1- Incidence 
According to the World Health Organization (WHO), there are anywhere from 
200-300 million cases of malaria per year resulting in approximately 1 million deaths 
annually. A majority of these deaths occur in children under 5 years of age, or adults 
over 60 years. Pregnant women have a higher susceptibility to P. falciparum, and as a 
result, up to 14% of infected mothers will give birth to children with low birth weight, 
further decreasing the infant's chance of survival (WHO, 2010). 
11 
Malaria occurs most frequently in central Africa, south Asia, and South America; 
according to the Center for Disease Control (CDC}, 35 countries in these areas account 
for 98% of all malaria-related deaths, 30 of which are located in Africa alone. Further, 
the CDC has calculated that approximately half the world's population (around 3.3 
billion) lives in regions with a risk of malaria infection. The disease is most prevalent in 
regions high in heat and humidity; in fact, at temperatures below 68° F, P. falciparum is 
unable to complete its growth cycle, thus preventing it from becoming transmissible. 
Among infectious diseases, malaria is the second leading cause of death in Africa behind 
HIV/AIDS, and is the fifth leading cause of disease-related death worldwide (CDC, 2010). 
The incidence of malaria around the world is shown in Figure 2. 
~ Mal'aria tra nsmission 
occurs througho u,t 
D Mal1aria. transmission 
occurs m some pa rts 
D Mal1aria transmission 
is not known to occur 
Figure 2 - Malaria occurrences throughout the world. (CDC, 2010) 
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1.2 - Current Detection Methods 
1.2.1- Peripheral Blood Smear 
The current "gold standard" for malaria detection is the blood film, also known 
as a peripheral blood smear. In a blood smear, a blood sample is removed from the 
patient and a drop is placed on a standard glass microscope slide and then analyzed 
under a microscope to determine parasite counts and species. There are two types of 
smears - thin and thick smears. In a thick smear, a drop of the target blood is placed on 
the center of a microscope slide with a cover slip on top; in a thin smear, second 
spreader slide is used to spread the blood down the length of the slide, the purpose of 
which is to spread the cells in the blood far enough apart to identify and count. Thick 
smears are performed to determine if any Plasmodium parasites are present in the 
sample; the larger volume (as opposed to a thin smear) makes a thick smear over ten 
times more sensitive, and thus, much easier to detect the present of any parasites 
(Warhurst, 1996). However, what thick films gain in sensitivity, they lose in specificity; 
the physical appearance of the parasites are distorted by large blood volumes, which 
makes the thin smear ideal for determining the species of Plasmodium present. 
The average observed detection limit of thick blood smears is around 50,000 
trophozites/ml, with a thin smear detection limit of 50,000,000 trophozites/ml or 
higher (Moody, 2000). Blood smears are considered to be the gold standard for 
Plasmodium detection due to its ability to accurately identify both an active infection as 
well as the type of species present with the same experimental setup. However, blood 
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smears require individuals trained in distinguishing between Plasmodium species; the 
species are distinguishable based on the unique ring-shaped structures that their 
membranes take on in the trophozite stage. As illustrated in Figure 3, discerning 
differences between the various Plasmodium species at a microscopic level is very 
difficult. Standard protocol requires that at least 200 separate visual fields must be 
analyzed prior to reporting a result. This, in addition to the standard staining 
procedures, results in assay times around 2-8 hours in length, depending on the number 
of personnel available for analysis (Stauffer, 2009). 
Figure 3 - Microscopy of Plasmodium species. A) P. fa/ciparum B) P. ovale C) P. 
malariae D) P. vivax. (Keas, 1999) 
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1.2.2 - ELISA 
A popular alternative to blood smears in malaria detection is the enzyme linked 
immunosorbent assay (ELISA}. The technique is used to identify antibodies or antigens in 
a sample, and thus requires at least one antibody specific to the target. In a typical ELISA 
test, the sample is introduced to a multi-well microtiter plate with a capture antibody 
immobilized to the bottoms of the wells. A washing phase follows; then, a second 
detection antibody bound to an enzyme is introduced to the samples. Lastly, a substrate 
is added to the samples, and the enzyme converts the substrate into a detectable form 
(Crowther, 2001). Using a antigen specific to P. falciparum, the ELISA assay has a 
detection limit as low as 18 trophozites/ml and a specificity of 100% (Sure Bio-
Diagnostics, 2009}. Including sample preparation time, typical ELISA assay times are on 
the order of 2-3 hours. 
1.2.3-PCR 
Polymerase chain reaction (PCR} is a DNA amplification technique that can also 
be used to detect for malaria. PCR is based on the concept of thermal cycling, or 
repeated cycles of heating and cooling periods, in order to promote DNA replication. 
Double-stranded DNA is exposed to high temperatures (above 90° C} min order to 
promote DNA melting, which causes the strands to separate. Short primer sequences 
that are complementary to the 3' end of the strands are introduced to the solution, and 
free nucleotides will being to build complementary strands to the previously denatured 
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double-stranded DNA. This process is repeated in order to generate multiple copies of 
the sequence of interest (Johnston, 2006). Previous studies have revealed that PCR has a 
P. falciparum detection limit ranging from 470-1200 trophozites/ml with 100% 
specificity (Mangold, 2005). PCR has a slight longer assay time than ELISA, taking around 
4-5 hours to produce detectable concentrations of P. falciparum sequences. 
1.3 - Detection by lmmunoagglutination 
1.3.1- Overview 
A relatively new means of pathogen detection is known as the particle 
immunoagglutination assay. Like the previously described methods, 
immunoagglutination is capable of pathogen detection in a biological sample matrix, but 
has the potential for significantly faster assay times with a simpler procedure while 
maintaining comparable detection limits. 
The basis of immunoagglutination relies on the use of latex particles for 
detection. Antibodies, either monoclonal or polyclonal, are conjugated with sensitized 
latex particles, which typically vary in size from 100 µm to 10 nm; particles must 
typically be a minimum of 50 µmin order to be easily viewed under a microscope (Gella, 
1991). The antibody-particle complex is then introduced to the target sample; in theory, 
the target will specifically bind to the antibodies present on the latex particles, forming a 
larger complex that can be detected through a variety of different means (Molina-
Bolivar, 2005}. Figure 4 illustrates the basic concept of immunoagglutination. 
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.. 
Figure 4- Standard particle immunoagglutination assay. 
1.3.2 - Mie Scattering 
One sensing method that can be used to detect for the presence of 
immunoagglutination is optical light scattering based off the Mie principle (Equation 1). 
!_ = 1+ cos 2 0 (2rc)4 (n2 -1)2 (~)6 
10 2R 2 ii. n 2 +2 2 
(1) 
where I = scattering intensity, 10 = incident light intensity, 8 = scattering angle, R = 
distance to the particle, A= wavelength, n = refractive index, and d = diameter of a 
particle. Developed by German physicist Gustav Mie in the 1930s, the Mie principle 
presents a set of solutions to Maxwell's equations that approximate the light scatter 
caused by particles. Mie scattering is accurate for particles that are larger than the 
wavelength of the scattered light, as particles that are significantly smaller than the 
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wavelength of the incident light scatter light based off the Rayleigh principle (Kerker, 
1969). Mie scattering and how it differs from Rayleigh scattering can be observed in 
Figure 5. 
irection • ch:Jent r ht 
Figure 5 - Comparison of Rayleigh and Mie scattering. 
',. 
¥ 
M. Scattering. 
larg:er par, · oles 
Figure 6 - Visualization of immunoagglutination-induced light scatter; the incident beam (bottom) does 
not scatter due to a lack of complexes (left), but will scatter in the presence of antibody-particle-target 
complexes. 
Mie scattering can be used to detect the presence of immunoagglutination by 
illuminating a sample containing antibody-particle complexes with a fixed light source 
and measuring the change in light scatter that results from the increased size of the 
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antibody-particle-target complex. The light scatter created by immunoagglutination is 
visualized in Figure 6. 
1.3.3 - Lab-on-Chip Diagnostics 
A problem inherent to nearly all classical methods of pathogen detection is the 
need for a facility in which to perform the necessary diagnostics. Blood smears require 
the use of a high-powered microscope, which are typically sensitive to motion and 
vibration; ELISA requires storage methods for the various antibodies and enzymes 
involved with the process as well as a plate reader for analyzing the wells; and PCR 
requires not only storage for the DNA primers and fragments needed for amplifications, 
but also a thermocycler to heat and cool the samples in order to promote DNA 
replication. In recent decades, lab-on-chip technology has sought to integrate multiple 
laboratory functions into small, channeled chips that are typically no larger than a few 
inches. Further, lab-on-chip devices can be manufactured from a variety of materials, 
including glass, polydimethylsiloxane (PDMS), and various metals and ceramics. Lab-on-
chip devices offer many potential advantages over standard laboratory environments, 
including significantly decreased space requirements, faster assay/analysis times, lower 
sample volumes, increased thermal control due to shortened diffusion distances 
(typically on the order of millimeters), and increased productivity due to the ease of 
running parallel experiments (Oosterbroek, 2003) 
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1.4 - Objectives 
1.4.1- Rapid Portable Detection Method for Malaria 
As previously mentioned, although current malaria detection methods are both 
sensitive and specific, they possess characteristics that limit their usefulness in field 
studies, such as the use of expensive microscopy equipment, lack of portability due to 
the need for large laboratory environments, diagnostic times that may take several days 
(including sample transport}, and requiring personnel trained in the use of all the 
aforementioned equipment. Given that a majority of clinical malaria cases take place in 
underdeveloped countries that typically lack proper medical facilities, there exists a 
need for a portable, inexpensive, and quick method for diagnosing malaria. 
Combining the principles of latex particle immunoagglutination, Mie scattering, 
and lab-on-chip diagnostics, this study will focus on the development of a hand held 
pathogen detection device for use in the rapid diagnosis of malaria in human whole 
blood samples. Such a device will be battery powered and its form factor will allow it to 
be carried by any average person, and thus, can be carried to just about any location in 
order to diagnose samples. Further, in order to be clinically relevant, it will be able to 
detect parasites in human whole blood samples with a minimal amount of sample 
processing. The entire device will be relatively low cost and easily reproduced, and 
compared to other detection methods, will be user-friendly without requiring specific 
training. 
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2.1- Experimental Overview 
Section 2 
Methods and Materials 
The main focus of the experimental procedure is to determine the optimal 
procedure for detecting pathogens in human whole blood, verify that the chosen 
antibodies bind specifically to target malaria antigens, and validate the hand held 
device's ability to detect for immunoagglutination of malaria antigens to latex 
nanoparticle-antibody complexes. 
2.2 - Handheld Device 
2.2.1 - Physical Construction 
The handheld's frame was designed by Hyuck-Jin Know and Scott Angus of the 
University of Arizona's biosensor laboratory using SolidWorks 2009. The form factor is 
9" L x 7.0625" W x 1.75" D and weighs approximately 3 lbs. The body is constructed of 
black acrylonitrile butadiene styrene (ABS) plastic, and rapid-prototyped using a Statasys 
Dimension 1200ES printer. The face contains an LCD screen and five buttons, which 
comprise the primary user interface, displaying light scatter levels and allowing the user 
to calibrate the device. There are two ports on either side of the device, a female Type-B 
USB port and a female +9V DC input, both of which can be used to power and/or charge 
the device. Lastly, the bottom of the device features a removable tray that accepts a 3" 
L x 1" W microfluidic chip, in which the sample and antibody-particle complexes are 
analyzed (Kwon, 2010). The final device is shown in Figure 7. 
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Figure 7 - Completed hand held detection device, with microfluidic tray removed. 
2.2.2 - Electronics 
The primary purpose of the electronics in the hand held system is to convert light 
scatter readings into a quantifiable metric for detecting immunoagglutination. There are 
six primary components to the electronics, which are detailed in Table 1; the major 
components are labeled in Figure 8. 
Table 1 - Overview of handheld electronic components. 
Component Description Input Type Output Type 
LED/Photodiode Pair Illuminates sample with light and 640 nm (red) Current (mA) 
records forward scatter light 
Differential Op-Amp Convert current output of Current (mA) Voltage (V) 
Circuit photodiode into voltage 
Arduino Duemilanove Microcontroller circuit that Voltage (V) Voltage (V) 
converts output for display on LCD 
screen 
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LCD Display 
4.7V Lithium Battery 
+SV /USB Power Board 
LED Intensity Adjustment 
Op-amp Zero Adjust 
Batte ry Charger 
DC-DC Stepup 
Displays light scatter levels in 
numeric form 
Allows device to function without a 
plug-in power supply 
Converts battery output to +SV and 
allows for charging via USB cable 
Main Circuit Board 
APD Op-amp Amplifier 
LED Power Supply and Switch 
Voltage Inverter 
24-bitADC 
Buzzer 
6Ah Lithium Ion Battery 
Voltage (V) Text (Numbers) 
n/a Voltage (V) 
Voltage (V) Voltage (V) 
Arduino Microcontrolle r 
LED and APO 
Holder 
Microflu idic 
Waveguide Chip 
Sample Tray 
Figure 8 -Inside view of device with electronics labeled. 
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With the exception of the differential op-amp circuit, all of the electronics 
components are off-the-shelf parts available at any reputable electronics supplier. 
The op-amp circuit is designed with a series of transimpedance amplifiers, the 
purpose of which is to convert a current signal into a voltage signal. This is necessary 
due to the fact that a photodiode outputs a current signal, and the Arduino only accepts 
voltage inputs. The LED driver is also integrated into the amplifier board, the purpose of 
which is to generate a constant light output from the LED. The schematic for the main 
board is shown in Figure 9, the final assembled board is shown in Figure 10, and the 
complete bill of materials is shown in Table 2. 
+SV cascading Differential Op-Amps 
luf 
1 8 
LED 2 7 N/C 6 2 
LTC1477 
+SV~ 3 6 N/C 
O.lufr 4 5 
1 0.luf LTC2105 ,1f-------i +SV 4 Reference 
lOuF 
8 
Arduino +SV 
2 7 PinlO 
Arduino LED Driver LTC2400 
6 Arduino 3 Pin12 N/C 1 8 
lOuF 
5 Arduino 2 7 N/C 4 ILC7660 
Pin13 lOuF 3 6 N/C 
4 5 --SV 
A/D 
lOufr Converter +9Vinverter 
Figure 9 -Amplifier circuit and LED driver schematic. 
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Figure 10 - Final assembled amplifier board . 
Table 2 - Main board bill of materials. 
Item 
No. Qty Ref Des Description Part# 
1 1 LT1021 L T1021 5V Reference L T1021 DCS8-5#PBF-ND 
2 1 LT2400 L TC2400 24 bit ADC L TC2400CS8#PBF-ND 
3 1 LT1477 L TC1477 Switch L TC1477CS8#PBF-ND 
4 6 C1-C6 1 00pF Capacitor BC2657CT-ND 
5 4 I C1 - I C4 10uF Capacitor P975-ND 
1477C1, 
6 2 2400C1 0.1 uF Capacitor 399-4266-ND 
7 3 OPA1-OPA3 IC Socket - 8 pin DIP A24807-ND 
8 3 OPA1-OPA3 TL082A Amplifier 296-1781-5-ND 
9 1 BZR Buzzer 102-1153-ND 
R1-R4; R7-R10; 
10 12 R13-R16 1 0kO Resistor RNF14FTD10K0CT-ND 
R5-R6; R11-
11 5 R12; R17 1 00kO Resistor RNF14FTD1 00KCT-ND 
12 1 BZR R1 1 ooo Resistor CF14JT100RCT-ND 
13 1 1477 C2 1 uF Capacitor BC 1157CT-ND 
14 1 7660 ICL7660 Voltage Converter ICL7660CPAZ-ND 
15 1 Headers Terminal Headers SAM1111-32-ND 
16 2 POT1-POT2 1 0kO Potentiometer 3296W-103LF-ND 
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The operational amplifier cascade consists of six total stages, four of which are set 
up as gain stages, and two of which are zero adjust stages. Each gain stage has a gain of 
10, with an overall circuit gain of 10,000 amps/volt, as the photodiode output is on the 
order of several nanoamps. The two zero adjust stages are used to calibrate the voltage 
output of the circuit through the use of 10 kO potentiometers which are user-adjustable 
through holes in the face of the handheld. The LT1021 is used to provide a stable +SV 
reference to the circuit, and helps maintain consistent light emission from the LED. The 
LTC2400 analog-to-digital converter allows for communication with the Arduino 
microcontroller board. The LTC1477 is a high side switch for controlling the LED. The 
ICL7660 outputs a fixed -SV output in order to power the negative rails of the op-amps. 
Lastly, the aforementioned Arduino microcontroller board converts the voltage output 
of the amplifier cascade to a digital signal that can be read by the LCD in order to display 
the amount of forward light scatter as an integer value. 
The optical detection portion of the electronics consists of a 640nm (red) LED and 
an avalanche photodiode. There are three primary factors that led to the using an 
LED/photodiode pair- cost, availability, and previous studies. LEDs and photodiodes are 
inexpensive, easily replaced, a have small form factors. Although laser diodes and 
photomultiplier tubes are viable and potentially more sensitive alternatives, it is 
believed that a laser diode would be too directional for scatter-based detection, and 
photomultiplier tubes are significantly larger than photodiodes. Photodiode/LED pairs 
were also readily available through most major electronics suppliers. Lastly, red light 
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was chosen based off its performance compared to blue (470 nm) and ultraviolet {375 
nm) light. Mie scattering simulations by You et al. observed the amount of light scatter 
difference between singlet particle models (in which only a single particle is bound to an 
antigen) and triplet models (in which three particles are bound to a single antigen) over 
a range of scatter angles. At the optimal scattering angle of 45°, ultraviolet produced 
the greatest scatter change, and blue produced the least amount of change. However, 
for angles.±. 5° from optimal, there is a significant roll-off in the intensity curve; this 
could affect the stability of readings if the scatter angle were to change. Although red 
light didn't yield as high of a change as ultraviolet did, its intensity curve was flatter. 
Thus, red light was chosen because it offered the best compromise between light 
intensity change and reproducibility (You, 2011). The referenced Mie scattering 
simulations are shown in Figure 11. 
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Figure 11 - Mie scattering simulations for red, blue, and ultraviolet light in both singlet and triplet forms. 
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2.2.3 - Microfluidic Chip 
The microfluidic chip was originally designed by Brian Heinze of the University of 
Arizona's biosensor laboratory; it features a Y-channel design with two wells for 
inserting the target and antibody-particle complexes into the test channel, waveguides 
for accepting fiber optic cables, and a port at the end of the Y-channel that can accept a 
syringe for mixing the sample and evacuating the channels. The chip is constructed from 
PDMS, and has a form factor of 311 L x 111 W x 0.2511 D. The chip layout is detailed in 
Figure 11. 
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Figure 12 - Microfluidic test chip. a) Two inlets for administration of target antigens and nanoparticles. b) 
Waveguide fill ports. c) Incident waveguide, connected to the 640 nm LED. d) Back scatter waveguide (not 
used for this experiment). e) Forward scatter waveguide. 
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The chips are fabricated from a silicone master mold, which was created through 
photolithography combined with deep reactive ion etching (DRIE}. To minimize loss 
during etching, a 6 µm thick photoresist (AZ 4620) was used as the silicon etching mask. 
C4F8 and SF6 combined with 0 2 were used for the passivation and etching steps. PDMS is 
poured into the mold and cured for one hour in a convection oven. Peeling the PDMS 
from the mold exposes the Y-channel, which is then bonded to a second PDMS through 
oxygen plasma treatment. The channels measure 1 mm wide by 100 µm in depth, with 
the waveguide channels measuring 750 µm wide by 100 µm in depth. The waveguide 
channels are designed to accept 100 µm diameter optic fiber cables sourced from Ocean 
Optics. The waveguide fill ports allow for the waveguide channels to be filled with 
microscope immersion oil Type A, with a refractive index of 1.515 (Nikon, 2010). A 
syringe in combination with Teflon tubing was used to deliver the oil; this same 
combination was also connected to the end of the Y-channel in order to pull the 
samples from the wells and mix them in the central channel (Heinze, 2010}. The 
completed assembly with fiber optic cables is shown in Figure 12. 
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Figure 13 - Completed microfluidic detection assembly. The upper-right fiber optic cable delivers the 
incident light from the 640nm LED, with the lower-left cable receives the forward-scattered light from the 
sample and delivers it to the photodiode. The teflon tube near the top of the picture is connected to a 
syringe in order to mix the sample and empty the channel. 
The forward scattering waveguide lies at an angle of 45° relative to the incident 
waveguide; this allows for scattered light collection anywhere from 40° to 70° relative to 
the incident angle. As previously observed by Heinze et al, the optimal angle for 
detecting forward scatter is 45°, based on both Mie scattering simulations and 
experiments for the detection of E. coli in liquefied lettuce samples (Heinze, 2011). 
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2.3- HRP-2 Antigen Preparation 
Due to the high cost of acquiring and culturing live strains of malaria, 
recombinant antigens were chosen as the target for this study, which are non-infectious 
and suitable for use in a Biosafety level-2 level laboratory. Specifically, histidine-rich 
protein 2 (HRP-2) recombinant antigens were chosen, which were acquired from 
Merdian Life Science, Inc. (Meridian Life Sciences, 2011). HRP-2 is a water-soluble 
protein specific to P. falciparum, and has been successfully detected in several rapid 
diagnostic tests over the past decade (Kakkilaya, 2003). Shipped from Meridian Life 
Sciences in a concentration of 6.65 mg/ml, the samples were first diluted to 1 mg/ml 
using a 20 mM carbonate buffer with a pH of 9.6, using 0.1% sodium azide as a 
preservative. Then, the antigens were serially diluted down to a minimum concentration 
of 1 pg/ml; the experiment was designed to detect for HRP-2 antigens ranging in 
concentration from 1 pg/ml to 100 µg/ml. 
2.4 - Nanoparticle Preparation 
Carboxylated polystyrene nanoparticles, high in acid content (15% acrylic acid) 
with a mean diameter of 920 nm in diameter, were chosen for this malaria study due to 
their success in previous immunoagglutination experiments (Kwon, 2010). A pair of 
monoclonal antibodies specific to HRP-2 were obtained, one designed for capture with 
the second designed for detection (Meridian Life Science, 2011). The monoclonal 
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antibody pair was covalently attached to the nanoparticles according to a procedure 
written by the Bangs Laboratories. The nanoparticles were first suspended in a 2-(N-
morpholino}ethanesulfonic acid (MES} activation buffer (C6H13NO4S, 50mM, pH 6.0, 
Sigma-Aldrich}. The particles were washed through centrifuge at 9.9g for 15 minutes 
followed by removal of and resuspension in MES; this was repeated two times. 1-ethyl-
3-(3-dimethylaminopropyl} carbodiimide (Fluka Analytical, Sigma-Aldrich} was then 
added to the nanoparticle suspension to serve as the primary linker between the 
antibodies and the particles. The suspension was then mixed constantly at room 
temperature for 15 minutes. Two additional washing periods followed, in which the 
particles were centrifuged for 22 minutes at 12g and resuspended in a coupling 
polymerase buffer solution or PBS (50mM, pH 7.4, Sigma-Aldrich}. Next, a total of 7.6 µL 
of antibodies at a concentration of 1 mg/ml were added to the solution (3.8 u= µL of 
each monoclonal antibody} in PBS coupling buffer; this volume should theoretically 
result in 100% coverage of the particles, but as observed by Yoon, only covers 30-50% of 
the particles in practice (Yoon, 2008). The antibody concentration is calculated using 
Equation 2: 
S = 6C 
pD (2) 
where S is the concentration required for total saturation, and 6C/p is the 
surface area to mass ratio based on a nanoparticle diameter, and D is the nanoparticle 
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diameter (You, 2011). The solution is then mixed overnight on a rocker at 4°C. Three 
additional washing periods followed, with 22 minutes of centrifuge at 12g followed by 
resuspension in PBS. After the third washing period, the solution was resuspended in 
hydroxylamine (40mM with 1% bovine serum albumin [BSA], Sigma-Aldrich, and mixed 
constantly at room temperature for 30 minutes. The solution was mixed one more time 
and resuspending with a storage buffer, PBS-BN (PBS with 1% BSA and 0.05% sodium 
azide, Sigma-Aldrich). The particle solution was stored at 4°C until used (Bangs, 2008). 
2.5 - Blood Sample Preparation 
Human whole blood was obtained from Interstate Blood Bank; the sample was 
Type O with heparin anticoagulant, and was stored at 4°C until use. After 30 seconds of 
vortex mixing, the blood was aliquoted into ten separate vials, nine of which were 
spiked with the varying concentrations of HRP-2 antigen formed by serial dilution in 
section 2.3- HRP-2 Antigen Preparation. The tenth vial served as the control, where 
S0mM PBS was used in place of HRP-2 antigen. The samples were then serially diluted in 
PBS to 10% and 1% of whole blood. 
2.6- Salmonella Preparation 
Salmonella enterica samples were obtained from Meridian Life Science and had 
an initial concentration of 7.9 colony-forming units (CFUs)/mL. Samples were cultured in 
a 90% brain heart infusion broth for 24 hours in order to reach a final concentration of 
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approximately 9 CFU/ml. The Salmonella sample was then serially diluted down to 1 
CFU/ml, and added to the whole blood samples described in section 2.5 - Blood Sample 
Preparation. Additional nanoparticles were conjugated with polyclonal Salmonella 
antibodies according to the procedure described in section 2.4 - Nanoparticle 
Preparation. 
2.7- Experimental Procedure 
2.7.1- Blood Sample Optimization with Salmonella Target 
The first objective of the experimental procedure was to determine the 
detection limit of pathogens in human whole blood. Due to the high cost of HRP-2 
antigens, Salmonella target was substituted for these optimization experiments. 
Salmonella was chosen specifically due to being low-cost and readily available in our 
laboratory; although the size of live bacteria in Salmonella would be much larger than 
HRP-2 antigens, they would be useful in determining what was the minimum blood 
dilution required for pathogen detection in human blood. Whole blood samples with 
dilution factors of 10% and 1% were examined using 20 µL two-well slides using an 
Ocean Optics USB4000 fiber optic benchtop spectrometer. Ocean Optics Spectrasuite 
software for Windows, connected via USB cable to the spectrometer, was used to 
monitor the light scatter levels. The software displayed the amount of light scatter as an 
integer over a range of wavelengths, with region of interest lying between 640-660 nm. 
The Spectrasuite interface is shown in Figure 13. 
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Figure 14 - Spectrasuite software for benchtop sprectrometer detection . 
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A 1:1 ratio of target to antibody conjugated particles was used for all 
experiments. Additionally, a polysorbate-80 nonionic surfactant was introduced to the 
samples just prior to detection in order to stabil ize the nanoparticles (Tween-80, 0.02% 
ml/ml, pH 7, Sigma-Aldrich). For each 20 µl well, 14 µl PBS buffer was combined with 7 
µl of diluted whole blood with Salmonella, 7 µl of nanoparticles, and 2 µl of surfactant 
for a total volume of 30 µl; this volume was chosen in order to mitigate the chance of 
air bubbles forming in the well . A l.8xl.8 mm glass cover slip was placed over the well, 
which was then centered underneath the 640 nm light source; a photodiode 
underneath the well measured the amount of forward light scatter. The Spectrasuite 
software was used to determine the intensity of the forward light scatter in the 
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wavelength region of interest. Two additional control trials were performed: the 
positive control substituted 50mM PBS in for the diluted blood, and the negative control 
used nanoparticles without any antibody bound to them. 
For all experiments, the blank is taken to be diluted whole blood in the absence 
of target; since each experiment is normalized to itself, the intensity change of each trial 
can be directly compared to another trial. 
2.7.2- lmmunosensing of HRP-2 with Benchtop Detection System 
The second experiment was designed to validate the detection of 
immunoagglutination of HRP-2 antigens in whole blood using the Y-channel microfluidic 
chip. Detection was again determined using the USB4000 spectrometer and the 
Spectrasuite software. Again using a 1:1 ratio of target to nanoparticles, 15 µL of 10% 
diluted whole blood with HRP-2 was added to one well of the Y-channel, while 15 µL of 
nanoparticles were added to the other well. Since HRP-2 was present in the whole, 
untreated blood, the concentration of HRP-2 was reduced by the same dilution factor as 
the blood. Just prior to detection, 2 µL of surfactant was added to the whole blood well, 
and a 1 ml syringe attached to the port at the end of the channel was used to draw the 
blood and particles into the central channel. An image of the experimental setup is 
shown in Figure 14. Since the purpose of this experiment was only to confirm the ability 
to detect HRP-2 in whole blood using the microfluidic chip, no additional trials were 
performed. 
Figure 15 - Experimental setup for microfluidic chip validation. 
2.7.3 - lmmunosensing of HRP-2 with Handheld Device 
The third experiment was designed to validate the detection of 
immunoagglutination of HRP-2 antigens using the handheld device. The experimental 
procedure was largely identical to the one described in Section 2.7.2, with the exception 
that the benchtop device was replaced by the hand held device. Bare 100 µm fiber optic 
cables were inserted into the waveguides, and microscope immersion oil was added to 
the waveguides until no air bubbles were present between the end of the cable and the 
central channel. The microfluidic chip and optic cables were then inserted into the 
removable test tray as shown in Figure 12. 
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A total of five trials were performed - three whole blood experiments and two 
controls. As in the previous experiments, the blood experiments detected for HRP-2 in 
10% diluted whole blood, the PBS positive control detected for HRP-2 in 50 mM PBS, 
and the negative control detected for HRP-2 using nanoparticles that had no antibody 
bound to them. 
2.7.4- Specificity Tests 
The final experiment was designed to verify that the chosen monoclonal 
antibody pair was specific to HRP-2 antigens. Using the same experimental procedure 
detailed in Section 2.7.3, nanoparticles bonded to the HRP-2 antibody pair were 
introduced to 10% whole blood with Salmonella target in the microfluidic chip and 
detected using the handheld device. Again, Salmonella was chosen specifically for its 
low cost and availability in the lab, not because it shares much in common with HRP-2 
antigens. 
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Section 3 
Results 
3.1 - Blood Sample Optimization with Salmonella Target Results 
The results of the experiments with Salmonella target using two-well slides and 
the benchtop spectrometer are shown in Figure 15. For all results, lines connecting the 
data points are included to aid in visualization. 
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Figure 16 - Change in light scatter vs. Salmonella concentration in various whole blood dilutions, tested in 
a two-well slide using a benchtop spectrometer. 
In 10% whole blood, a maximum intensity change of 66.8% was observed at a 
Salmonella concentration of 103 CFU/ml; in 1% blood, the maximum intensity change 
was 26.7% at 102 CFU/ml; in PBS, the maximum observed change was 12.6% at 102 
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CFU/ml. A linearly increasing trend was observed over at least two orders of magnitude 
for all trials; in 10% blood, this trend was observed over three orders of magnitude. 
For the positive control experiment using a PBS medium, a maximum signal change of 
12.6% was observed at a Salmonella concentration of 102 CFU/ml; for the negative 
control experiment using particles without antibody attached, the maximum signal 
change was 2% at 109 CFU/ml with an average change of 1% over all concentrations. 
3.2 - lmmunosensing of HRP-2 with Benchtop Detection System Results 
The results of the HRP-2 validation experiments in 10% whole blood with the 
microfluidic chip using the benchtop spectrometer are shown in Figure 16. 
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Figure 17 -Change in light scatter vs. HRP-2 concentration in 10% whole blood, tested in a 
microfluidic chip using the benchtop detection system. Standard error bars may be too small 
to be viewed for some data points. 
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A linearly increasing trend with an R2 value of 0.9925 was observed over nine 
orders of magnitude, with a minimum intensity change of 2.2%, and a maximum change 
of 49.3%. The largest standard deviation was calculated to be 0.79% at 100 µg/ml with a 
standard error of 0.46%. 
3.3 - lmmunosensing of HRP-2 with Hand held Device Results 
The results of the experiments with HRP-2 target in 10% whole blood using the 
microfluidic chip and handheld detection device are shown in Figure 17; the average of 
the three blood experiments with statistical analysis is shown in Figure 18. 
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Figure 18 - Change in light scatter vs. HRP-2 concentration in 10% whole blood, tested in a 
microfluidic chip using the hand held device 
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Figure 19-Average of all blood trials presented in Figure 17 with standard error bars. 
All trials demonstrated a linear trend over nine orders of magnitude. The 
maximum observed signal change during Trial 1 was 44.3%, with a minimum change of 
4.9% and an R2 value of 0.9861; during Trial 2, the maximum change was 28%, and the 
minimum was 4.7% and an R2 value of 0.9834; during Trial 3, the maximum change was 
62.9%, and the minimum was 8.4% and an R2 value of 0.9155. The largest standard 
deviation was calculated to be 21.4% at 1 µg/ml with a standard error of 12.37%. For 
the positive control experiment using a PBS medium, a maximum signal change of 26.7% 
was observed at an antigen concentration of 100 µg/ml, ; for the negative control 
experiment using particles without antibody attached, the maximum signal change was 
3.7% at a concentration of 100 pg/ml, with an overall average change of 2.38%. The 
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largest standard deviation of 0.0.66% was observed at 10 µg/ml, with a standard error 
or 0.38%. 
3.4 - Specificity Results 
The results of the HRP-2 monoclonal antibody pair specificity tests are shown in 
Figure 20. 
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Figure 20 - HRP-2 specificity experiments with Salmonella target in a microfluidic chip using the 
handheld 
detection device 
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A maximum signal change of 1.37% was observed at a Salmonella concentration 
of 108 CFU/ml, with an overall average change of 0.84%. The largest standard deviation 
of 0.42% was calculated at a concentration of 104 CFU/ml, with a standard error or 
0.24%. 
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Section4 
Discussion 
4.1- Detection of lmmunoagglutination in Human Whole Blood 
Prior to validating the handheld's ability to detect for immunoagglutination, we 
had to first determine the optimal human whole blood preparation method. Preliminary 
tests showed that undiluted whole blood proved to be too protein-rich in order to 
determine whether scatter was a result of protein excess or immunoagglutination of the 
target to the nanoparticles. Thus, blood dilutions became necessary and dilutions as low 
as 0.01% were tested. Every dilution also resulted in an order of magnitude loss of 
antigen concentration; dilutions below 1% resulted in a 99% reduction in target 
concentration, leading to an excess of particles relative to antigens in the detection 
sample. Increased blood dilution factors also extend assay times, making the lowest 
detectable dilution factor ideal for short assay times. The purpose of administering the 
target pathogens to whole blood prior to dilution was to make the samples as clinically 
relevant as possible; introducing the diluted blood to the pathogens would result in 
artificially high detection limits. 
As shown in Figure 16, immunoagglutination of Salmonella in blood dilutions of 
10% and 1% were detectable, with the 10% dilution proving to be over 50% more 
sensitive than the 1% dilution. The control experiments were designed to ensure that 
increased light scatter was a result of specific immunoagglutination between the 
nanoparticles and Salmonella target, not increased antigen concentration or other 
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phenomena. There is a minimum of a 10% change in intensity between the lowest 
measured value of the 10% diluted blood and the highest measured value of the control 
blood without particles. Although control experiments weren't performed on the 1% 
diluted blood, there is at least a 2% intensity change difference between the lowest 
measured value of the 1% diluted blood and the highest measured value of the 10% 
control blood; this data indicates that the observed increase in light scatter is in fact the 
result of antibody-nanoparticle-target complex formation. The experiment involving 
nanoparticles with no bound antibody produced no greater than a 1% change from the 
lowest to highest Salmonella concentrations; this flat trend indicates that nanoparticles 
bound to polyclonal Salmonella antibodies are selectively binding to Salmonella target 
and not other proteins in the blood. It should be noted that the decreasing trend 
observed after 103 CFU/ml is an optical phenomenon also observed in previous studies 
using f. coli and Salmonella. 
4.2 - lmmunosensing of HRP-2 Antigens 
The purpose of the benchtop testing of the microfluidic chip was to validate the 
chip as an effective testing environment and determine if the chosen HRP-2 antibody 
pair was capable of binding HRP-2 antigen. A linearly increasing change in scatter was 
observed over all concentrations of HRP-2, with a small standard deviation over the 
course of several trials. Although the benchtop spectrometer represents an idealized 
detection method due to being less prone to variation in output (as noted by a standard 
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deviation less than 1%), it verified that immunoagglutination of HRP-2 antigens to the 
nanoparticles was possible in diluted whole blood. 
The results of the hand held testing closely resemble those of the benchtop tests, 
with increasing light scatter over the range of HRP-2 antigen concentrations with a 
detection limit of 1 pg/ml, albeit with a larger standard deviation. The specificity test 
showed that there was less than a 1% change in intensity throughout the range of 
Salmonella concentrations, with a maximum observed change of 1.37% from the blank, 
verifying that the HRP-2 antibodies do not cross-react with Salmonella target and 
demonstrating 100% specificity for this experiment. 
It should be noted that the measured light scatter during Trial 3 was significantly 
higher than the values measured in Trials 1 and 2. This may be a result of build-up of 
blood proteins on the channel walls. Although the channels are designed to promote 
laminar flow, if blood cells were to bind to the channel walls, then light scatter would 
increase over the course of the experiment due to a buildup of blood cells. In order to 
mitigate channel wall contamination, the channels were washed with PBS after every 
blood trial. In order to verify that increased scatter was not due to build-up on the 
channel wall, the order of experiments for Trial 2 was reversed, such that the highest 
concentration of HRP-2 was tested first, and the lowest concentration was tested last. 
Since the same linear trend was present, it was determined that the blood had no short-
term effects on the channel walls. However, the data from Trial 3 shows that the light 
scatter increased dramatically for HRP-2 concentrations above 1 ng/ml, contributing to 
a relatively large standard deviation for concentrations between 10 ng/ml and 100 
µg/ml. Thus, it is possible that the chip is only accurate for a finite number of trials 
before the channel wells either break down or begin to suffer from contamination. Since 
the microfluidic chips are designed to be disposable, this would not detract from the 
handheld's performance in the field as the chips would be disposed of after each 
experiment. 
It should also be noted that the measured light scatter in the positive control 
PBS sample was no higher than in any of the blood samples; PBS represents the ideal 
sample environment, as it is theoretically clear and devoid of other molecules, making 
any light scatter the result of immunoagglutination only. However, since a majority of 
blood is composed of blood cells and albumin, we expect that overall scatter would be 
higher; the fact that light scatter remains relatively constant over increasing antigen 
concentration indicates that increased light scatter is a result of an increased number of 
antibody-nanoparticle-antigen complexes, not proteins in the blood. Further, the 
increased scatter caused by antigens in blood may also be due to the presence of 
human serum albumin, which is the most abundant of the human blood plasma 
proteins. A recent study by Kaminski et al revealed that albumin, which has been used 
in previous studies to mitigate nonspecific cell adhesion to target substrates, has a 
propensity to bind to unmodified polystyrene surfaces (Kaminski, 2011). Since the HRP-2 
antibody pair only covers 30-50% of the nanoparticle surface, it is likely that albumin in 
the blood attaches to those unbound surfaces and stabilizes the particle, resulting in 
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increased binding to the HRP-2 target and ultimately, a higher degree of measured light 
scatter. 
4.3 - Significance 
4.3.1- Comparison with Current Detection Methods 
There are two primary advantages that the hand held has over current detection 
methods - decreased assay time and portability. As the majority of malaria occurrences 
are in sub-Saharan Africa, Asia, and South America, where proper testing facilities may 
be few and far between, the overall detection time is typically lengthened by several 
days to account for the time it takes to transport the sample to a test facility. Since the 
onset of symptoms due to P. falciprum can occur in less than a week from the time of 
infection, those days can mean the difference between mild symptoms and death. 
Hence, the ability to bring the detection device to the outbreak region is a significant 
leap forward for malaria detection, and can reduce assay times anywhere from a few 
days to a week. 
The detection limit and the specificity of the hand held device is on par with 
blood smears, ELISA, and PCR. The detection limits of the various methods are 
summarized in Table 3. Note that all detection limits have been converted from 
trophozites/mL to pg/ml so that all methods could be directly compared. This was done 
using the assumption that the volume of a mature trophozite could be approximated as 
a sphere, that a trophozite's diameter is 15 µm, and that its density was 1 g/ml (3). 
Density = G rrr3 ) n (3) 
Where r is the diameter of the trophozite and n is the number of trophozites in 
one ml, as expressed in Section 1.2. 
Table 3 - Detection method comparison 
Sensitivity (pg/ml) 
Sensitivity Assay Time 
Method 
(trophozites/ml) 
Thick blood smear 88 50,000 1-8 hours 
Thin blood smear 88000 50,000,000 1-8 hours 
ELISA 32 18,000 2-3 hours 
PCR 2 1,000 4-5 hours 
Handheld device 1 500 5-8 minutes 
The hand held demonstrated the lowest detection limit of all the various malaria 
detection methods; although obviously more sensitive than blood smear tests, the 
sensitivity of ELISA and PCR varies depending on the study, so the handheld is at the 
very least comparable to these two methods. However, the hand held is superior to both 
ELISA and PCR in terms of assay time; whereas the former methods require several 
hours to perform, a test on the hand held device can be performed in five minutes. The 
assay times in Table 3 do not reflect any additional time required to transport the blood 
samples from the draw site to the lab. While additional trials beyond this study would 
be needed in order to confirm the statistical relevance of the handheld's detection limit, 
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we can determine that the hand held is a viable method of detecting for p. fa/ciparum 
parasites in human whole blood. 
Potential issues with P. falciparum detection using the hand held device include 
the possibility of false positive as well as false negatives. Since this experiment tests for 
the presence of HRP-2 proteins in the blood and not live parasites, it could yield a false 
positive after a malaria infection has already been treated, as the protein levels will 
remain high in the blood even after the parasites have been removed. Further, there is 
evidence that not all P. falciparum parasites express HRP-2 (Ndao, 2004}. Thus, this 
experiment would be unable to detect any such P. falciparum parasites, resulting in a 
false negative. In order to mitigate the chance of false negatives, further study would be 
required in order with live parasites in order to determine what other proteins they 
specifically express; targeting proteins in addition to HRP-2 may decrease specificity, but 
could eliminate the chance of missing an active infection. 
4.3.2 - Applications 
With comparable detection limits to the current malaria detection standards 
coupled and increased portability, the handheld device has potential applications in any 
area of the world in which is prone to malaria infection. The small form factor and 
battery could allow it to be taken into regions whose geography would limit the 
usefulness of other detection methods due to the amount of time required to travel to 
and from the regions, as blood samples can be affected by long transit times. 
so 
Additionally, since the device was able to detect both Salmonella and HRP-2 in 
blood samples, it could theoretically be modified to detect for a variety of pathogens by 
binding specific antibodies to the nanoparticles. 
4.3.3 - Cost Analysis 
A summary of the cost to replicate the hand held device is shown in Table 4. 
Table 4 - Summary of handheld build cost. 
Item Vendor Cost 
Main circuit fabrication Advanced Circuits $350 
Main circuit components Digi-Key $20 
Arduino Sparkfun $30 
LCD Display Sparkfun $18 
Misc. electronics Sparkfun $30 
Lithium-ion battery Sparkfun $40 
Microfluidic chip n/a $0.50 
ABS housing PADT $500 
Total -$988.50 
The cost to replicate the device is just under $1000; however, the cost per unit 
could be reduced considerably through mass-production of the device, which would 
drive down the cost of the most expensive components {the main circuit board and the 
rapid-prototype housing} down by 80% or more. 
Compared to the cost of other detection methods, with the exception of blood 
smears, the initial cost of creating a single hand held device is higher than a single ELISA 
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or PCR kit. Table 5 shows examples of the costs associated with the various malaria 
detection methods. 
Table 5- Cost comparison of various malaria detection methods. 
Method Equipment Cost Reagent Cost Work Hours Cost per Test 
Blood smears $1500-2000 $0 2 $40 
ELISA $22,000-29,000 $550 2 $46 
PCR $3500-6500 $425 4 $84 
Handheld Device $200-1000 $150 0.15 $5 
As shown above, the cost of the hand held device is roughly double that of a PCR 
or ELISA kit specific to P. falciparum, but about half as expensive as a microscope for 
blood smears. However, the ELISA and PCR kits have a finite number of uses; since each 
kit contains a 96-well slide, a maximum of 96 tests can be administered per kit. Thus, for 
larger populations, the cost to purchase multiple kits will exceed the cost of a single 
handheld device, which has a lifespan of several years and only requires inexpensive 
PDMS chips for additional experiments. The cost per test was calculated by multiplying 
the number of work hours times by arbitrary rate of $20 (a reasonable hourly wage for a 
laboratory technician) and adding it to the reagent cost per test. The equipment costs 
were obtained from current market values; blood smears require a microscope, ELISA 
requires a plate reader, and PCR requires a thermocycler. Blood smear tests require no 
additional reagent, as the blood samples are simply placed on microscope slides for 
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analysis. For ELISA and PCR, 96-well kits are purchased which contain everything 
necessary for their respective tests. For the hand held device, the reagent cost only 
consists of purchasing antibodies and microfluidic chips; since only 7.6 µLare used for 
each set of particles, the cost of antibodies is nearly negligible as many tests can be 
performed with a single vial. The handheld device had both the lowest initial cost as well 
as the lowest cost per test, making it a cost-effective method for accurately detecting 
HRP-2 antigen in human blood. 
4.4- Future Work 
There are two major components which could benefit from future improvement -
the electronics and the microfluidic chip itself. The main circuit board consists entirely of 
leaded, discrete components, which are typically reserved for non-sensitive applications 
due to the increased capacitance of the leads as well as the potential for mechanical 
failure. A switch to surface-mount components would increase the mechanical strength 
of the board considerably, while increasing overall electrical stability of the. Further, the 
size of the op-amp cascade could be decreased from six amplifiers to as few as two by 
switching to precision instrumentation amplifiers, such as the Texas Instruments 
INA128, which could also increase the stability of the voltage output. The orientation of 
the photodiode could also be adjusted for increased sensitivity; currently, it is set up in 
reverse-bias mode, which is optimized for speed at the cost of reduced sensitivity. 
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However, this additional speed is unnecessary for this particular circuit; forward-biasing 
the photodiode would increase sensitivity without any noticeable performance loss. 
The main limitation of the Y-channel chip is that in order to maintain accurate 
results, the device must be recalibrated between experiments due to the single channel 
design; this increases the overall assay time, and increases the chance of user-error. An 
improved design would consist of two isolated channels, each with a unique 
LED/photodiode pair for detection. One channel would be used for the clinical sample, 
while the other would contain a control sample. This would allow the user to quickly 
determine the difference in light intensity change, as well as identify abnormalities with 
either of the samples. 
Although the form factor of the hand held is significantly smaller than other 
detection systems, it's sized could be decreased further through merging all of the 
electronics onto a single, custom circuit board. As shown in Figure 8, a majority of the 
interior of the device is dedicated to the individual circuits and their interconnections; 
merging all of the circuits together with smaller, surface mount components could 
decrease the overall size of the device by 40% or more. 
One issue that would need to be addressed prior to commercialization of the 
hand held device would be creating a long-term storage method for the antibody-
conjugated particles. In the laboratory, the particles required storage at 4° C; however, 
in order to be a truly portable device, the particles would require transportation without 
the need for a refrigerator. One way to do this would be to lyophilize the nanoparticle-
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antibody complexes prior to travelling to the test site; this would eliminate the need for 
a refrigerator, and only require a small cooler with dry ice in order to keep the particles 
stable. 
Specificity tests against Salmonella were performed in order to gauge how well the 
chosen HRP-2 antibodies selectively bound to the HRP-2 antigens; however, since the 
Salmonella target consisted of full-sized bacteria, they have little in common with the 
recombinant HRP-2 antigens. Thus, more rigorous testing would need to be performed 
in order to validate the hand held device's specificity; this could be accomplished 
through testing for cross-reactions between HRP-2 antibodies and antigens from other 
Plasmodium species, such as HRP-1 and AMAl. 
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